Hikma Pharmaceuticals PLC

LSE HIK.L

Hikma Pharmaceuticals PLC Price to Book Ratio (P/B) on February 03, 2025: 2.87

Hikma Pharmaceuticals PLC Price to Book Ratio (P/B) is 2.87 on February 03, 2025, a 18.10% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Hikma Pharmaceuticals PLC 52-week high Price to Book Ratio (P/B) is 2.87 on January 31, 2025, which is 0.06% above the current Price to Book Ratio (P/B).
Hikma Pharmaceuticals PLC 52-week low Price to Book Ratio (P/B) is 2.27 on April 17, 2024, which is -20.66% below the current Price to Book Ratio (P/B).
Hikma Pharmaceuticals PLC average Price to Book Ratio (P/B) for the last 52 weeks is 2.52.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

LSE: HIK.L

Hikma Pharmaceuticals PLC

CEO	Mr. Riad Ali Mishlawi
IPO Date	Nov. 1, 2005
Location	United Kingdom
Headquarters	1 New Burlington Place
Employees	9,100
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Consumer Packaged Goods Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Key trends

Past 5 years